Drug Trial Radar · NCT06079983
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Last checked: Nov 20, 2026Latest source record: Sep 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Dec 1, 2023
Primary completion
Apr 1, 2026
Study completion Mar 1, 2029
Sponsor
- Lead sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Oct 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized controlled, open-label, multicenter phase III clinical study evaluating the efficacy and safety of chemotherapy selected by investigator JSKN003 s in subjects with recurrent or metastatic breast cancer who have previously failed first- or second-line chemotherapy in subjects with recurrent or metastatic breast cancer who have failed prior first- or second-line chemotherapy. The study planned to enroll 408 subjects in a 1:1 ratio and stratified block randomization method assigned to: * Experimental group: JSKN003 monotherapy * Control group: investigator's chosen chemotherapy drug (capecitabine, gemcitabine, vinorelbine, docetaxel, albumin-bound paclitaxel, or eribulin) monotherapy
Conditions
- Breast Cancer
Interventions
JSKN003Drug
Administered intravenously according to protocol.
Capecitabine tabletsDrug
Administered according to protocol, as one option for investigator's choice (determined before randomization).
Gemcitabine hydrochloride for injectionDrug
Administered according to protocol, as one option for investigator's choice (determined before randomization).
Vinorelbine tartrate injectionDrug
Administered according to protocol, as one option for investigator's choice (determined before randomization).
Paclitaxel for injection (albumin-bound type)Drug
Administered according to protocol, as one option for investigator's choice (determined before randomization).
Docetaxel injectionDrug
Administered according to protocol, as one option for investigator's choice (determined before randomization).
Eribulin mesylate injectionDrug
Administered according to protocol, as one option for investigator's choice (determined before randomization).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: up to approximately 3 years after the first enrollment
Locations
87 sites in 1 country. Site status is shown where the registry gives one.
Anyang Cancer Hospital
Anyang, China · Not yet recruiting
Affiliated Hospital of Hebei University
Baoding, China · Not yet recruiting
Beijing Luhe Hospital
Beijing, China · Not yet recruiting
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, China · Recruiting
Peking University Cancer Hospital
Beijing, China · Recruiting
The First Affiliated Hospital of China Medical University
Beijing, China · Recruiting
The First Medical Center of the General Hospital of the People's Liberation Army Chinese People's Liberation Army
Beijing, China · Not yet recruiting
Bethune First Hospital of Jilin University
Changchun, China · Not yet recruiting
Jilin Provincial Cancer Hospital
Changchun, China · Not yet recruiting
The First People's Hospital of Changde
Changde, China · Recruiting
Central South University Xiangya Hospital
Changsha, China · Not yet recruiting
Hunan Cancer Hospital
Changsha, China · Recruiting
Affiliated Hospital of Chengde Medical University
Chengde, China · Recruiting
Sichuan Cancer Hospital
Chengdu, China · Recruiting
Sichuan Provincial People's Hospital
Chengdu, China · Recruiting
West China Hospital, Sichuan University
Chengdu, China · Not yet recruiting
Cancer Hospital of Chongqing University
Chongqing, China · Not yet recruiting
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China · Not yet recruiting
The Second Affiliated Hospital of Dalian Medical University
Dalian, China · Not yet recruiting
Fujian Cancer Hospital
Fuzhou, China · Not yet recruiting
Fujian Provincial Hospital
Fuzhou, China · Recruiting
Union Hospital Affiliated to Fujian Medical University
Fuzhou, China · Recruiting
The First Affiliated Hospital of Gannan Medical University
Ganzhou, China · Recruiting
Guangdong Provincial People's Hospital
Guangzhou, China · Not yet recruiting
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, China · Not yet recruiting
The Affiliated Hospital of Guangdong Medical University
Guangzhou, China · Recruiting
Sun Yat-sen University Cancer Center
Guanzhou, China · Not yet recruiting
Guizhou Provincial People's Hospital
Guiyang, China · Recruiting
The Affiliated Hospital of Guizhou Medical University
Guiyang, China · Recruiting
Harbin Medical University Cancer Hospital
Ha’erbin, China · Not yet recruiting
Run Run Shaw Hospital affiliated to Zhejiang University School of Medicine
Hangzhou, China · Not yet recruiting
The First Affiliated Hospital of Zhejiang University School of Medicine
Hanzhou, China · Not yet recruiting
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hanzhou, China · Not yet recruiting
Zhejiang Cancer Hospital
Hanzhou, China · Not yet recruiting
Anhui Provincial Hospital
Hefei, China · Not yet recruiting
The First Affiliated Hospital of Anhui Medical University
Hefei, China · Not yet recruiting
The Second Affiliated Hospital of Anhui Medical University
Hefei, China · Not yet recruiting
The First Affiliated Hospital of University of South China
Hengyang, China · Recruiting
Affiliated Hospital of Inner Mongolia Medical University
Hohhot, China · Recruiting
Jiangmen Central Hospital
Jiangmen, China · Recruiting
Showing 40 of 87 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.